Advances in Brief Ras Oncogene-Induced Sensitization to 1-bD-Arabinofuranosylcytosine 1

Human tumor cells containing ras oncogenes display enhanced sensitivity to 1b-D-arabinofuranosylcytosine (Ara-C) and other deoxycytidine analogues (H-M. Koo, et al., Cancer Res., 56: 5211–5216, 1996). Human tumor cell lines with or without a rasoncogene as well as a pair of isogenic cell lines with one containing an activatedrasoncogene were used to study the basis for differential sensitivity. We found that human tumor cells containing ras oncogenes upon entry into the S phase of the cell cycle underwent apoptosis in response to Ara-C treatment. By contrast, human tumor cells harboring wild-type ras alleles were only delayed in the S phase when exposed to Ara-C. Thus, the ras oncogene specifically renders human cells more sensitive to Ara-C by preventing S-phase arrest. This may occur by the ras oncogene compromising an S-phase checkpoint.

[1]  Y. Pommier,et al.  The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. , 1999, Journal of the National Cancer Institute.

[2]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[3]  Joseph R. Nevins,et al.  Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F , 1997, Nature.

[4]  T. Lister,et al.  Treatment of acute myelogenous leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W G Alvord,et al.  Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. , 1996, Cancer research.

[6]  R. Schlegel,et al.  Suppression of Apoptosis by Dominant Negative Mutants of Cyclin-dependent Protein Kinases (*) , 1996, The Journal of Biological Chemistry.

[7]  Y. Wang,et al.  Regulation of the cell cycle machinery by oncogenic ras. , 1996, Oncogene.

[8]  D. Bortner,et al.  Overexpression of cyclin A in the mammary glands of transgenic mice results in the induction of nuclear abnormalities and increased apoptosis. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[9]  A. Robles,et al.  Induction of cyclin D1 overexpression by activated ras. , 1994, Oncogene.

[10]  A. Morley,et al.  The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia. , 1994, Leukemia.

[11]  D. Bergstrom,et al.  Participation of cyclin A in Myc-induced apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Stephen S. Gisselbrecht,et al.  Activation of cyclin A-dependent protein kinases during apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  C. Bloomfield,et al.  Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia , 1994 .

[14]  D. Lydall,et al.  Cell cycle checkpoints, genetic instability and cancer. , 1993, Seminars in cancer biology.

[15]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[16]  M. Barbacid,et al.  ras oncogenes: their role in neoplasia , 1990, European journal of clinical investigation.

[17]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[18]  S. Grant,et al.  Ara-C: cellular and molecular pharmacology. , 1998, Advances in cancer research.

[19]  S. Kaufmann,et al.  Chemotherapy-induced apoptosis. , 1997, Advances in pharmacology.

[20]  Y. Rustum,et al.  1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. , 1992, Pharmacology & therapeutics.

[21]  D. Kufe,et al.  Biochemical and cellular pharmacology of cytosine arabinoside. , 1985, Seminars in oncology.